Bioactivity-guided screening identifies pheophytin a as a potent anti-hepatitis C virus compound from Lonicera hypoglauca Miq.

Biochemical and Biophysical Research Communications

Volumn 385, Issue 2, 2009, Pages 230-235

  Wang, Sheng Yang ^a   Tseng, Ching Ping ^b   Tsai, Keng Chang ^c   Lin, Chia Fan ^d   Wen, Ching Ya ^d   Tsay, Hsin Sheng ^e   Sakamoto, Naoya ^f   Tseng, Chin Hsiao ^g   Cheng, Ju Chien ^d  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHAOYANG UNIVERSITY OF TECHNOLOGY   (Taiwan)

^f TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatitis C virus; Lonicera hypoglauca Miq.; Pheophytin a; Replicon cells

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; NONSTRUCTURAL PROTEIN 3; PHEOPHYTIN A; PLANT EXTRACT; SERINE PROTEINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME INHIBITION; GENE EXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; LONICERA HYPOGLAUCA; MEDICINAL PLANT; MOLECULAR MODEL; NONHUMAN; PLANT LEAF; PLANT STEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON;

ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CELL LINE; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HEPACIVIRUS; HUMANS; INTERFERON ALFA-2A; LONICERA; MODELS, MOLECULAR; PHEOPHYTINS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS; LONICERA;

EID: 67349091694     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.05.043     Document Type: Article

References (24)

1. Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., Watanabe Y., Koi S., Onji M., Ohta Y., Choo Q.L., Houghton M., and Kuo G. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Sci. Acad. USA 87 (1990) 6547-6549
2. Mangia A., Santoro R., Minerva N., Ricci G.L., Carretta V., Persico M., Vinelli F., Scotto G., Bacca D., Annese M., Romano M., Zechini F., Sogari F., Spirito F., and Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352 (2005) 2609-2617
3. Lai M.Y. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan. Intervirology 49 (2006) 91-95
4. Pu Z., Xing J., Li P., Liu T., and Wang Z. Studies on the floral morphology of Flos Lonicerae. Zhong Yao Cai 25 (2002) 854-859
5. Xu Y., Oliverson B.G., and Simmons D.L. Trifunctional inhibition of COX-2 by extracts of Lonicera japonica: direct inhibition, transcriptional and post-transcriptional down regulation. J. Ethnopharmacol. 111 (2007) 667-670
6. Yoo H.J., Kang H.J., Song Y.S., Park E.H., and Lim C.J. Anti-angiogenic, antinociceptive and anti-inflammatory activities of Lonicera japonica extract. J. Pharm. Pharmacol. 60 (2008) 779-786
7. Lohmann V., Körner F., Koch J., Herian U., Theilmann L., and Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
8. Blight K.J., Kolykhalov A.A., and Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 290 (2000) 1972-1974
9. Choi J., Lee K.J., Zheng Y., Yamaga A.K., Lai M.M., and Ou J.H. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39 (2004) 81-89
10. Tanabe Y., Sakamoto N., Enomoto N., Kurosaki M., Ueda E., Maekawa S., Yamashiro T., Nakagawa M., Chen C.H., Kanazawa N., Kakinuma S., and Watanabe M. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J. Infect. Dis. 189 (2004) 1129-1139
11. Blight K.J., McKeating J.A., and Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76 (2002) 13001-13014
12. Cheng J.C., Chang M.F., and Chang S.C. Specific interaction between the hepatitis C virus NS5B RNA polymerase and the 3′ end of the viral RNA. J. Virol. 73 (1999) 7044-7049
13. Kato T., Date T., Murayama A., Morikawa K., Akazawa D., and Wakita T. Cell culture and infection system for hepatitis C virus. Nat. Protoc. 1 (2006) 2334-2339
14. Di Marco S., Rizzi M., Volpari C., Walsh M.A., Narjes F., Colarusso S., De Francesco R., Matassa V.G., and Sollazzo M. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J. Biol. Chem. 275 (2000) 7152-7157
15. Tanabe Y., Sakamoto N., Enomoto N., Kurosaki M., Ueda E., Maekawa S., Yamashiro T., Nakagawa M., Chen C.H., Kanazawa N., Kakinuma S., and Watanabe M. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J. Infect. Dis. 189 (2004) 1129-1139
16. Ina A., Hayashi K., Nozaki H., and Kamei Y. Pheophytin a, a low molecular weight compound found in the marine brown alga Sargassum fulvellum, promotes the differentiation of PC12 cells. Int. J. Dev. Neurosci. 25 (2007) 63-68
17. Tallarida R.J. Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther. 298 (2001) 865-872
18. Pause A., Kukolj G., Bailey M., Brault M., Dô F., Halmos T., Lagacé L., Maurice R., Marquis M., McKercher G., Pellerin C., Pilote L., Thibeault D., and Lamarre D. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J. Biol. Chem. 278 (2003) 20374-20380
19. Duan D., Li Z., Luo H., Zhang W., Chen L., and Xu X. Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease. Bioorg. Med. Chem. Lett. 14 (2004) 6041-6044
20. Zuo G., Li Z., Chen L., and Xu X. Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res. 76 (2007) 86-92
21. Zhou Y., Bartels D.J., Hanzelka B.L., Muh U., Wei Y., Chu H.M., Tigges A.M., Brennan D.L., Rao B.G., Swenson L., Kwong A.D., and Lin C. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 52 (2008) 110-120
22. Bartels D.J., Zhou Y., Zhang E.Z., Marcial M., Byrn R.A., Pfeiffer T., Tigges A.M., Adiwijaya B.S., Lin C., Kwong A.D., and Kieffer T.L. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198 (2008) 800-807
23. He Y., King M.S., Kempf D.J., Lu L., Lim H.B., Krishnan P., Kati W., Middleton T., and Molla A. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob. Agents Chemother. 52 (2008) 1101-1110
24. Okai Y., and Higashi-Okai K. Potent anti-inflammatory activity of pheophytin a derived from edible green alga, Enteromorpha prolifera (Sujiao-nori). Int. J. Immunopharmacol. 19 (1997) 355-358